The future role of mass spectrometry in proteomics: Embracing new technologies and building bridges for higher impact

L. K. P. is the cofounder of Talus Bioscience, Inc., a company developing anticancer therapeutics using mass spectrometry proteomics. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.